Vesugen Dosage: Longevity Research Protocol

Read this first

Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.

Dosage chart

The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.

Vesugen · 20 mg Vial

Vesugen is dosed at 500 mcg–2 mg daily via subcutaneous injection in educational protocols. A Lys-Glu-Asp reconstituted with bacteriostatic water yields about 6.67 mg/mL.

Typical daily range: 500–2000 mcg once daily (gradual titration).

Standard / Gradual Approach

Week	Daily Dose (mcg)
Week 1	500 mcg (0.5 mg)
Week 2	1000 mcg (1.0 mg)
Week 3	1500 mcg (1.5 mg)
Weeks 4–8+	1500–2000 mcg (1.5–2.0 mg)

3 ml conversion

Select vial strength

20 mg + 3 ml = 6.67 mg/ml. Choose your vial strength to update the units below.

Source dose	U-100 syringe
500 mcg	7.5 units
1000 mcg	15 units
1500 mcg	23 units
2000 mcg	30 units

Source chart on peptidedosages.com

Other longevity compounds

CartalaxSynthetic tripeptide (Ala-Glu-Asp) bioregulator EpithalonSynthetic tetrapeptide (Ala-Glu-Asp-Gly)FOXO4-DRIFOXO4-p53 interaction-disrupting retro-inverso peptide GlutathioneEndogenous tripeptide antioxidant (Glu-Cys-Gly)Humanin24-amino-acid mitochondrial-derived peptide LivagenSynthetic tetrapeptide bioregulator

All research protocols

Vesugen: research background

What the compound is

Vesugen is a synthetic tripeptide with the amino acid sequence Lys-Glu-Asp (KED). It is one of several short peptides that have been studied for various biological effects (PMID 25051766, PMID 39518916).

How it is thought to work

Lys-Glu-Asp is believed to stimulate cell proliferation and inhibit apoptosis, which is programmed cell death (PMID 22977872). It can accelerate cell renewal processes, such as decreasing the apoptosis marker p53 and increasing the proliferation marker Ki-67 (PMID 22977872). In studies, Lys-Glu-Asp was found to interact with the promoter region of the MKI67 gene, which codes for the Ki-67 protein, suggesting an epigenetic regulation of its expression (PMID 25051766). It has also been linked to regulating the expression of genes involved in cell aging and apoptosis (p16, p21), neuronal differentiation (NES, GAP43), and Alzheimer's disease pathogenesis (SUMO, APOE, IGF1) (PMID 34173097).

What laboratory and animal studies report

In organotypic cultures of neuroimmunoendocrine system cells, Lys-Glu-Asp stimulated cell proliferation and reduced apoptosis. This effect was more pronounced in cultures from older animals than from young animals (PMID 22977872). Lys-Glu-Asp also induced expression of lymphocyte marker CD5 and macrophage marker CD68, with a less pronounced effect in older cultures (PMID 22977872). In tissue-specific cell cultures from young and old animals, Vesugen stimulated proliferation-associated protein Ki-67 (PMID 25051766). Lys-Glu-Asp (KED) can also restore synaptic plasticity in an in vitro model of Alzheimer's disease (PMID 34173097). In a cellular model of human neuronal aging, KED partially protected induced neurons from age-related changes and stimulated dendritogenesis, which is the growth of dendrites, a part of neurons (PMID 39518916). Lys-Glu-Asp (Vesugen) also stimulated differentiation factors in human prostatic fibroblasts, with a more pronounced effect in aged cell cultures (PMID 22808515).

Human evidence so far

Oral application of KED (Lys-Glu-Asp) improved memory and attention in elderly individuals diagnosed with functional central nervous system disorders (PMID 34173097). In a study with 32 individuals (41-83 years old) with polymorbidity and organic brain syndrome in remission, Vesugen demonstrated an anabolic effect, improving central nervous system activity and other vital organs, which was observed to slow the rate of aging by biological age indicators (PMID 26390612). The study also noted that Vesugen had a more visible geroprophylactic, or anti-aging, effect compared to another peptide, Pinealon (PMID 26390612).

Open questions and limitations

While some studies suggest Vesugen's potential effects, the cellular and metabolic aspects of its geroprotective actions require further investigation (PMID 26390612). Specifically, the mechanism of prooxidant activity observed through chemiluminescence and the significant inhibition of hematopoiesis (blood cell formation) indicated by decreased CD34+ positive hematopoietic pluripotent cells require more research (PMID 26390612). Although no effect on chromatin condensation was observed, confirming its safety at the nuclear genetic level, this property warrants further study (PMID 26390612). The effectiveness of neuroprotective peptide KED in animal models of Alzheimer's disease is noted as an important area for future study (PMID 34173097).

Key terms explained

**Apoptosis:** Programmed cell death, a normal process of cell turnover (PMID 22977872). **Ki-67:** A protein that serves as a marker for cell proliferation, indicating actively dividing cells (PMID 22977872). **P53:** A protein that can act as a tumor suppressor and is involved in regulating the cell cycle and apoptosis (PMID 22977872). **Synaptic plasticity:** The ability of synapses, the connections between neurons, to strengthen or weaken over time in response to activity, crucial for learning and memory (PMID 34173097). **Dendritogenesis:** The process of dendrite formation and branching, which are extensions of nerve cells that receive signals from other neurons (PMID 39518916). **Epigenetic regulation:** Changes in gene expression that do not involve alterations to the underlying DNA sequence but can influence how genes are read and translated into proteins (PMID 25051766).

Studies cited in this section

Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. — Bulletin of experimental biology and medicine, 2012 (PMID 22977872)
Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease. — Bulletin of experimental biology and medicine, 2021 (PMID 34173097)
[Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. — Advances in gerontology = Uspekhi gerontologii, 2014 (PMID 25051766)
Peptides tissue-specifically stimulate cell differentiation during their aging. — Bulletin of experimental biology and medicine, 2012 (PMID 22808515)
Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. — International journal of molecular sciences, 2024 (PMID 39518916)
[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]. — Advances in gerontology = Uspekhi gerontologii, 2015 (PMID 26390612)

Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.

Nearby in the protocol A–Z

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

Vesugen dosage protocol